BioPharmSignal logoBioPharmSignal

Biotech News

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

Vaxcyte (PCVX)Vaxcyte2026-06-25 13:46 ESTClinical readout

First-in-Human Study Evaluating VAX-A1, a Potential Best-in-Class Vaccine Candidate Designed to Provide Broad Protection Against Disease Caused by Group A Streptococcus Two-Stage, Dose-Escalation Study Designed with Primary Objective to Evaluate Safety and Tolerability and Secondary Objective to

Open original release

Related news

PCVXVaxcyte2026-06-25 13:46 EST

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-06-25 13:46 EST

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

PCVXVaxcyte2026-06-25 13:46 EST

Vaxcyte Announces Pricing of $550 Million Public Offering

PCVXVaxcyte2026-06-25 13:46 EST

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

PCVXVaxcyte2026-06-25 13:46 EST

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

PCVXVaxcyte2026-06-25 13:46 EST

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

PCVXVaxcyte2026-06-25 13:46 EST

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

PCVXVaxcyte2026-06-25 13:46 EST

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

PCVXVaxcyte2026-06-25 13:46 EST

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

PCVXVaxcyte2026-06-25 13:46 EST

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

View all latest news

Vaxcyte

Vaxcyte is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

PCVXVaxcyte2026-06-26 09:25 EST

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

PCVXVaxcyte2026-06-26 09:25 EST

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-06-26 09:25 EST

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

PCVXVaxcyte2026-06-26 09:25 EST

Vaxcyte Announces Pricing of $550 Million Public Offering

PCVXVaxcyte2026-06-26 09:25 EST

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States